As BCL-3 also directly drives N-cadherin expression in melanoma-derived cells56 and because KIAA1199-depleted CaSki cells had decreased N-cadherin expression despite intact BCL-3 protein levels, we conclude that BCL-3 controls the expression of mesenchymal markers through multiple mechanisms in transformed cells. The gene discussed is CDH2; the disease is melanoma.